Participated · Series A · Sep 2023

CellFE develops a microfluidics-based cell engineering platform focused on advancing development and manufacturing of advanced cell therapies. The platform emphasizes high cell health and payload delivery, streamlined scalability, and automated workflows. Reported benefits include increased cell yield and reduced expansion times, which the company says translate to shorter vein-to-vein times and lower manufacturing costs for advanced cell therapies. The company is led by CEO Alla Zamarayeva and is positioned to support both development and manufacturing workflows. CellFE intends to use recent financing to advance its technology platform and support market launch and growth initiatives. The company is based in Alameda, California. CellFE develops a microfluidics-based device that delivers gene-editing molecules into human cells using rapid cell compressions to drive uptake from the surrounding fluid. Led by CEO Alla Zamarayeva, the company focuses on applying microfluidics to enable engineering of next-generation cell therapies. The company is based in San Carlos, CA. It completed a $4.8M seed financing to accelerate development of its delivery solution. The round was co-led by Dynamk Capital and Cota Capital, with participation from Embark Ventures, Elm Ventures and McEwan Lane Family Trust. Investor representatives Dr. Gustavo Mahler (Dynamk Capital) and Bobby Yazdani (Cota Capital) will join the board of directors.